肝动脉化疗栓塞术中注入重组人血管内皮抑制素治疗中晚期肝癌的疗效及安全性分析

doi:10.3969/j.issn.1672-5069.2014.06.022

Abstract

Su Yu, Zhou Zhihong, Wang Qiang. Application of recombinant human endostatin in transcatheter arterial chemoembolization in treatment of patients with advanced hepatocellular carcinoma[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2014, 17(6): 644-647.

References

[1] Siegel R,Naishadham D,Jemal A. Cancer statistics.Ca Cancer J Clin,2012,62（1）:10-29.
[2] Maluccio M,Covey A. Recent progress in understanding,diagnosing,and treating hepatocellular carcinoma. Ca Cancer J Clin,2012,62（6）:394-399.
[3] 尹国文,陈世唏,陈森清,等.重组人血管内皮抑制素联合介入治疗肝癌. 中华实验外科杂志,2012,29（5）:978.
[4] 许飞,王永涛,史仲华,等. 多次肝动脉化疗栓塞术对原发性肝癌的疗效及对肝功能的影响.肿瘤学杂志,2011,17（11）:850-853.
[5] 林福煌,谢贤和,吴宁,等. TACE联合瘤内碘油化疗乳剂治疗肝癌疗效观察. 中国热带医学,2011,11（8）:989-991.
[6] 孙涛,周立群,李艳花.恩度联合介入治疗对肝癌血管生成抑制作用的研究. 现代肿瘤医学,2013,21（1）:122-123.
[7] 李勃,许晓莲.肝动脉化疗栓塞联合重组人血管内皮抑制素介入治疗原发性肝细胞癌. 中国肿瘤,2012,21（6）:466-468.
[8] Bao Y,Feng WM,Tang CW,et al.Endostatin inhibits angiogenesis in hepatocellular carcinoma after transarterial chemoembolization. Hepatogastroenterology,2012,59（117）:1566-1568.
[9] 高峰,黄祥忠,沈炜,等. 重组人血管内皮抑制素联合介入治疗肝细胞型肝癌的疗效及安全性. 山东医药,2011,51（13）:35-36.
[10] 彭静,邢辉,张铂,等.重组人血管内皮抑素在原发性肝癌介入治疗中的应用. 中国医药科学,2012,5（10）:66-67.
[11] 王永中.恩度静脉滴注联合介入化疗栓塞治疗中晚期肝癌的临床研究. 现代预防医学,2011,38（2）:399-401.
[12] 孙学栋,杜玉清,陈伟建.恩度对原发性肝癌TACE术后VEGF的影响. 实用肿瘤杂志,2013,28（1）:41-44.
[13] 徐强,黄优华,石红建,等. 肝动脉栓塞化疗联合恩度治疗原发性肝癌的临床研究. 实用临床医药杂志,2012,16（7）:63-65.
[14] 梁荣中. TACE联合重组人血管内皮抑制素介入治疗肝细胞癌临床分析. 中国热带医学,2013,13（4）:484-486.
[15] 廖明初,艾小红.奥沙利铂联合恩度介入治疗原发性肝癌疗效观察. 中南医学科学杂志,2013,41（5）:500-504.

Application of recombinant human endostatin in transcatheter arterial chemoembolization in treatment of patients with advanced hepatocellular carcinoma

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Zhu Yage, Liu Jinfeng.. Therapeutic efficacy of adenosine methionine and glycyrrhizin combination in treatment of patients with alcoholic cirrhosis and its effect on serum BGP levels [J]. Journal of Practical Hepatology, 2019, 22(6): 872-875.
[2]	Cao Ce, Yu Yixing, Wang Beibei, et al.. Clinical diagnostic efficacy of enhanced magnetic resonance imaging combined with serum AFP and PIVKA-Ⅱ in the diagnosis of patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2019, 22(6): 896-899.
[3]	Xing Hao, Han Jun, Yang Tian.. Diagnostic value of serum protein induced by vitamin K absence or antagonist II for hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2019, 22(6): 934-937.
[4]	Zhao Fangfang, Zhai Yongzhen, Feng Guohe. Efficacy and safety of autologous peripheral blood stem cell transplantation in patients with hepatitis B cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(5): 700-703.
[5]	Zhu Jun, Ding Ying, Wang Shiqing, et al. Peripheral blood Th22 cells and plasma interleukin-22 level changes in patients with hepatocellular carcinoma after hepatectomy and administration of ulinastatin [J]. Journal of Practical Hepatology, 2019, 22(5): 720-723.
[6]	Wang Gang, Zhao Hongbo, Zhu Yaling, et al. Cancerous XPO5 gene level in patients with hepatocellular carcinoma and its clinical significance [J]. Journal of Practical Hepatology, 2019, 22(5): 724-727.
[7]	Zhang Zhicheng, Yuan Guangqi, Mo Chanjun. Impact of blood supply on efficacy of hepatic artery embolization in treatment of patients with hepatic hemangioma [J]. Journal of Practical Hepatology, 2019, 22(5): 736-739.
[8]	Yan Lingling, Hu Donghui, Huang Yanfang. Influence of ademetionine combined with polyene phosphatidylcholine on clinical efficacy and laboratory index in patients with intrahepatic cholestasis of pregnancy [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 530-533.
[9]	Yuan Chunhui, Li Chunyu, Li Hongli. Efficacy of pegylated interferon α -2b in the treatment of patients with serum HBeAg positive chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 353-356.
[10]	Qiao Zhizhong. Value of contrast-enhanced ultrasonography in differential diagnosis of patients with focal nodular hyperplasia and hepatocellular carcinoma [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 421-424.
[11]	Ma Xiaosu, Pei Renming Zhang Tingting. Comparison of magnetic resonance cholangiopancreatography with color Doppler ultrasound in diagnosis of patients with common bile duct stones [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 433-436.
[12]	Zhu Guangxi，Wen Liangzhi，Chen Dongfeng. Pathogenesis of non-alcoholic fatty liver disease-related hepatocellular carcinoma [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 453-456.
[13]	Wang Huming, Fan Dongsheng, Xu Jie, Liu Xianfegn, Zhou Ning, Li Min, Bao Nana. Cancerous miRNA-30c levels affecting the survival of patients with hepatocellular carcinoma after hepatectomy [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 248-251.
[14]	Xing Diankui, Cheng Jing. Clinical value of ¹⁸F-FDG PET/CT scan in patients with hepatocellular carcinoma and hepatic microvascular invasion [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 252-254.
[15]	Wang Xiuqing, Ma Yanjun, Zhan Jinli. Efficacy of transcatheter arterial chemoembolization and ultrasound-guided microwave ablation in the treatment of patients with hepatocellular carcinoma at special sites [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 260-263.